FY2026 EPS Estimate for Urogen Pharma Lifted by Analyst

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Urogen Pharma to a loss of $0.77 per share from a forecast loss of $0.83, while maintaining a Buy rating and $75 price target.
• Analyst sentiment is broadly positive: eight analysts rate the stock Buy, one Hold and one Sell, for a consensus “Moderate Buy” rating and $53.38 average price target.
• Urogen’s latest quarter missed expectations, reporting a $0.03-per-share loss versus consensus EPS of $0.11 and revenue of $89 million versus estimates of $89.92 million.

Urogen Pharma (NASDAQ:URGN - Free Report) - Equities researchers at HC Wainwright boosted their FY2026 earnings per share estimates for Urogen Pharma in a research report issued on Thursday, November 5th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.77) per share for the year, up from their previous forecast of ($0.83). HC Wainwright has a "Buy" rating and a $75.00 price objective on the stock. The consensus estimate for Urogen Pharma's current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Urogen Pharma's Q4 2026 earnings at $0.02 EPS, Q1 2027 earnings at $0.02 EPS, Q2 2027 earnings at $0.07 EPS, Q3 2027 earnings at $0.21 EPS, Q4 2027 earnings at $0.28 EPS and FY2027 earnings at $0.59 EPS.

Other analysts have also recently issued reports about the stock. UBS Group reaffirmed an "outperform" rating on shares of Urogen Pharma in a research note on Thursday. Oppenheimer set a $60.00 price objective on shares of Urogen Pharma in a report on Thursday. The Goldman Sachs Group reiterated a "neutral" rating and issued a $44.00 target price on shares of Urogen Pharma in a research note on Wednesday, July 15th. Guggenheim reduced their target price on Urogen Pharma from $58.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $56.00 target price on shares of Urogen Pharma in a report on Thursday, September 10th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $53.38.

Urogen Pharma Price Performance

Shares of URGN stock opened at $24.75 on Monday. Urogen Pharma has a 12-month low of $16.50 and a 12-month high of $50.81. The company has a market capitalization of $1.21 billion, a P/E ratio of -18.75 and a beta of 1.68. The firm has a 50-day moving average price of $38.78 and a 200 day moving average price of $31.53.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.14). The firm had revenue of $89.00 million for the quarter, compared to analyst estimates of $89.92 million.

Insider Activity at Urogen Pharma

In related news, insider Mark Schoenberg sold 871 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $42.92, for a total value of $37,383.32. Following the transaction, the insider directly owned 59,882 shares in the company, valued at $2,570,135.44. This represents a 1.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Jason Smith sold 1,519 shares of Urogen Pharma stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total transaction of $64,618.26. Following the sale, the general counsel directly owned 53,141 shares of the company's stock, valued at $2,260,618.14. This represents a 2.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 65,269 shares of company stock valued at $3,037,646 over the last quarter. Corporate insiders own 4.80% of the company's stock.

Institutional Investors Weigh In On Urogen Pharma

Institutional investors have recently made changes to their positions in the stock. Sterling Capital Management LLC raised its position in shares of Urogen Pharma by 442.1% during the third quarter. Sterling Capital Management LLC now owns 1,339 shares of the company's stock worth $54,000 after purchasing an additional 1,092 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Urogen Pharma by 15.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,919 shares of the company's stock valued at $361,000 after purchasing an additional 1,165 shares during the period. Persistent Asset Partners Ltd acquired a new position in shares of Urogen Pharma in the 2nd quarter valued at approximately $66,000. Quantbot Technologies LP acquired a new position in shares of Urogen Pharma in the 2nd quarter valued at approximately $78,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Urogen Pharma during the 3rd quarter worth approximately $101,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Urogen Pharma Company Profile

UroGen Pharma Ltd. NASDAQ: URGN is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company's therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen's primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen's proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.